European Archives - Page 969 of 1330 - European Medical Journal

Prediction with Precision: Does TAILORx Make Chemotherapy a Personalised Treatment?

Adjuvant chemotherapy (CT) is commonly recommended to breast cancer patients following surgery. However, not all patients benefit from it, and the…

Congress Feature from ESMO 2018

During this year’s ESMO Congress, the EMJ team attended the three hotly- anticipated Presidential Symposia chaired by ESMO President Prof Josep Tabernero…

Patient Reports of Mouth Symptoms after Radiotherapy Treatment for Head and Neck Cancer: An International Survey

People with head and neck cancer frequently have symptoms that are caused by their disease or by their treatments, which may significantly impact on…

Genomic Profiling Clinical Trials in Cancer of Unknown Primary

Cancer of unknown primary (CUP) accounts for 3–5% of all cancers, and prognosis is poor for most patients, with a median survival of 6–9 months…

EMJ

Dr Mohammad Akheel

Consultant Head and Neck Oncosurgeon, Greater Kailash Hospitals, Indore, India…

New Immunotherapy Approaches for The Treatment of Cancer: Reported at the European Society for Medical Oncology Congress 2018

Immunotherapy is currently a pillar in the treatment of cancer, in addition to surgery, radiotherapy, chemotherapy, and molecular-targeted therapies.

Editor's Pick: Novel Targets and Therapies in T Cell Lymphoma

This review presents the recent advances in our understanding of the cellular pathogenesis of T cell non-Hodgkin lymphoma (NHL) and the potential of…

Major Determinants of Delayed Access to Innovative Medicines for Metastatic Melanoma: The Results of the Melanoma World Society (MWS) and European Association of Dermato-Oncology (EADO) Survey

At the 2018 European Society for Medical Oncology (ESMO) Congress in Munich, Germany, the Melanoma World Society (MWS) and European Association of…

Recent Advances in the Treatment of Metastatic Soft Tissue Sarcoma

Soft tissue sarcomas (STS) are a rare group of heterogeneous malignancies with >50 histologic subtypes that have varying biological behaviour and…

EMJ

Prof Dr Yves Chalandon

Head of the Hematology Division and of the BMT Program, Geneva University Hospitals, Geneva, Switzerland…